What is Biofrontera?
Biofrontera Inc. is a biopharmaceutical company headquartered in Woburn, Massachusetts, dedicated to the commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's product portfolio includes Ameluz, a prescription drug utilized in photodynamic therapy for actinic keratosis, and Xepi, a topical treatment for impetigo. Established in 2015, Biofrontera focuses on addressing pre-cancerous skin lesions and bacterial skin infections through its innovative therapeutic offerings.
How much funding has Biofrontera raised?
Biofrontera has raised a total of $17.5M across 2 funding rounds:
Debt
$6.5M
Private Equity
$11M
Debt (2023): $6.5M with participation from MidCap Business Credit
Private Equity (2025): $11M, investors not publicly disclosed
Key Investors in Biofrontera
MidCap Business Credit
MidCap Business Credit LLC is an independent commercial finance company which provides asset based loans for companies unable to obtain traditional bank financing.
What's next for Biofrontera?
The substantial enterprise-level funding and recent strategic investment position Biofrontera for accelerated growth and expanded market penetration. This capital infusion is expected to bolster the company's commercialization efforts for its key dermatological products, potentially enabling further research and development into new therapeutic areas or the enhancement of existing treatments. The company's trajectory suggests a focus on scaling operations and solidifying its market presence within the competitive biopharmaceutical landscape.
See full Biofrontera company page
